Pembrolizumab adjuvant (resected stage III/IV melanoma; KEYNOTE-054)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-PEMBROLIZUMAB`

ID	`REG-PEMBRO-ADJUVANT-MELANOMA`
Type	Regimen
Status	reviewed 2026-04-30 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-MELANOMA-2024` `SRC-KEYNOTE-054-EGGERMONT-2018` `SRC-NCCN-MELANOMA-2025`

Notes

KEYNOTE-054 / EORTC-1325 (Eggermont NEJM 2018, Lancet Oncol 2021 5-yr update): adjuvant pembrolizumab 200 mg q3w × 1 yr vs placebo in resected stage III melanoma (n=1019). 12-mo RFS 75.4% vs 61.0% (HR 0.57); 5-yr RFS 55.4% vs 38.3% (HR 0.61); benefit consistent across PD-L1+ and PD-L1- subgroups. Established adjuvant pembrolizumab for resected stage III; basis for FDA approval Feb 2019 + later expansion to stage IIB/IIC (KEYNOTE-716). Start within 12 weeks of surgery; complete 18 cycles unless recurrence / intolerance. Adjuvant nivolumab (CheckMate-238) is interchangeable alternative.

Used By

Indication

IND-MELANOMA-ADJUVANT-PEMBRO-STAGE-III - IND-MELANOMA-ADJUVANT-PEMBRO-STAGE-III

Regimen

REG-PEMBRO-ADJUVANT-NSCLC - Pembrolizumab adjuvant (resected NSCLC; KEYNOTE-671)